Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma

Author:

Choueiri Toni K.1,Powles Thomas1,Burotto Mauricio1,Escudier Bernard1,Bourlon Maria T.1,Zurawski Bogdan1,Oyervides Juárez Victor M.1,Hsieh James J.1,Basso Umberto1,Shah Amishi Y.1,Suárez Cristina1,Hamzaj Alketa1,Goh Jeffrey C.1,Barrios Carlos1,Richardet Martin1,Porta Camillo1,Kowalyszyn Rubén1,Feregrino Juan P.1,Żołnierek Jakub1,Pook David1,Kessler Elizabeth R.1,Tomita Yoshihiko1,Mizuno Ryuichi1,Bedke Jens1,Zhang Joshua1,Maurer Matthew A.1,Simsek Burcin1,Ejzykowicz Flavia1,Schwab Gisela M.1,Apolo Andrea B.1,Motzer Robert J.1

Affiliation:

1. From the Department of Medical Oncology, Lank Center for Genitourinary Oncology, Dana–Farber Cancer Institute, Brigham and Women’s Hospital, and Harvard Medical School, Boston (T.K.C.); the Department of Genitourinary Oncology, Barts Cancer Institute, Cancer Research UK Experimental Cancer Medicine Centre, Queen Mary University of London, Royal Free National Health Service Trust, London (T.P.); the Bradford Hill Clinical Research Center, Santiago, Chile (M.B.); the Department of Medical Oncology, Gustave...

Funder

Bristol-Myers Squibb Company

Ipsen Pharma

ONO Pharmaceutical Company Ltd.

Exelixis Inc.

Takeda Pharmaceutical Company Ltd.

Publisher

Massachusetts Medical Society

Subject

General Medicine

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3